We have another guest joining us this week! Dr. Allison Schepers, PharmD, BCOP is a Clinical Pharmacist Specialist at the Rogel Cancer Center at the University of Michigan where she focuses on GI, GU, and Thoracic malignancies! In this episode, Allison discusses the high yield points we need to know about important drugs we use in the colorectal cancer treatment space and how she approaches counseling her patients. Another great episode from our pharmacy colleagues you do NOT want to miss! Content: - Important considerations about capecitabine, oxaliplain, and irinotecan, backbones of our colorectal cancer management- An overview of targeted agents?- If someone has a reaction, can we retrial any of these drugs in the future? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week, we are joined by Dr. Christina Bailey, Associate Professor of Surgery and Program Director of the General Surgery Residency at Vanderbilt University Medical Center in Nashville, Tennessee, for a discussion about the role of surgery in the management of patients with colorectal cancer. This is another amazing multidisciplinary colorectal surgery episode you do not want to miss!Content: - Why are MRIs important as part of workup for patients with rectal cancer? - What is an "LAR" vs. "APR" and how do you decide which to use? - What are long term complications associated with rectal cancer surgery? - How much colon should be removed in a patient with colon cancer undergoing surgery? - How to counsel patients about colon resection?- How long after surgery should we wait for adjuvant chemotherapy in colon cancer? - Is there a role for neoadjuvant therapy in metastatic colon cancer? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week, we are joined by Dr. Nina Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology Service, UT Southwestern Medical Center in Dallas, Texas, for a discussion about the role of radiation in colorectal cancer, with an emphasis on the role of radiation in rectal cancer. Dr. Sanford is a wealth of knowledge so this is an episode you do NOT want to miss. Of note, rectal cancer episodes will be released in a few weeks so if all of this does not make sense, don’t worry. It nicely sets the stage for what is to come! Content: - What is the role of radiation in rectal cancer vs. colon cancer? Why do we use it more in rectal cancer?- How to evaluate your patients for radiation and how to decide long course vs. short course radiation - Side effects of radiation therapy for rectal cancer- Role of radiation for oligmetastatic colorectal cancer** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this week’s episode, we discuss the management of stage II colon adenocarcinoma, which is defined by a lack of nodal involvement and invasion through the muscularis layer of the colon. If you have not done so already, be sure to check out episode 099 (overview of colorectal cancer) and episode 100 for stage III colon cancer, as we will building on concepts discussed already. Content: - Is there a role for adjuvant chemotherapy in stage II colon cancer patients? - What is the impact on MSI/MMR testing in stage II colon cancer patients? - Is there a role for evaluating circulating tumor DNA (ctDNA) in colon cancer patients? - Is there a role for immunotherapy in the adjuvant setting?** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week, we kick off our discussion of adjuvant systemic treatment in colon cancer, beginning with Stage III colon cancer. We will review the evidence basis for adjuvant therapy as well as the two main chemotherapy regimens including duration and side effects. Content: - Why do we need adjuvant therapy in stage III colon cancer? - What is FOLFOX? What is CAPOX? When do we use what?- What is the optimal duration of therapy? - What are the characteristics deemed high risk? - Can we discontinue oxaliplatin early? - What is the role of oxaliplatin in older patients? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Colorectal cancer is one of the most common cancers diagnosed each year worldwide. This highly anticipated series will take an in-depth look at this disease. In this first episode, we discuss the basics, including staging, tumor markers, and microsatellite instability testing, before tackling the management of colorectal cancer in upcoming episodes. Content: - What is the incidence of colorectal cancer (CRC) in the US?- How are CRC patients staged? - What is the role of CEA? - What are microsatellites and mismatch repair proteins, and how do they come into play for treatment purposes?- Who needs germline testing? - What is the TNM staging for CRC? - What are some high risk factors we need to pay attention to on the pathology report? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

With multiple options for frontline therapy in CLL, MRD has the potential to emerge as a factor that could be considered in our decision-making algorithm for sequencing treatment options. In this week’s episode, we dive into a deeper understanding of the role of MRD testing in CLL. Content: - What is the role of MRD testing in CLL?- What are the techniques we use to evaluate for MRD?- What is the prognostic role of MRD testing? - Is there data to change treatment based on MRD testing?** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Dive into the complexities of managing relapsed chronic lymphocytic leukemia (CLL) with insights on treatment strategies and patient care. Discover the challenges of diagnosing Richter's transformation and the impact of key therapies like obinutuzumab and venetoclax. Learn about the significance of genetic markers in prognosis and the evolving landscape of second-line treatments, including the implications of recent market withdrawals. Nostalgic discussions about childhood animated films add a light-hearted touch to this serious topic.

Delve into the latest advancements in chronic lymphocytic leukemia treatment, exploring crucial indications for therapy and the debate between fixed versus indefinite options. A complex case study reveals the challenges faced by a patient with multiple health issues. Discover the intricacies of managing associated autoimmune conditions and the significance of monitoring approaches. Key insights on novel therapies, including BTK inhibitors and venetoclax, are shared, shedding light on personalized treatment strategies and their implications for patient care.

Dive into the world of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) as the hosts share personal clinical experiences. Discover insights about diagnosing CLL, the mystery of smudge cells, and the importance of B cells. They debunk common myths and emphasize that patients can often live well without aggressive treatment. Plus, explore advancements in risk stratification and the role of molecular testing in tailored patient care. And don’t miss out on some recommended winter wines to enjoy while you listen!